Alternate Name(s):
2-CdA, LEUSTATIN
Classification:
Antineoplastic, Antimetabolite - CYTOTOXIC
Original Date:
August 2005
Revised Date:
November 2023
Indications:
- Relapsed or refractory leukemias, lymphomas
- Refractory Langerhans Cell histiocytosis (investigational)
THIS MEDICATION IS TO BE ADMINISTERED BY A CHEMO-TRAINED NURSE. IF THE NURSE IS NOT CHEMO-TRAINED, THEY ARE TO CONTACT THE UNIT NURSE EDUCATOR OR ADVANCED PRACTICE NURSE.
Reconstitution and Stability:
- Supplied as a 1 mg/mL, 10 mL vial
- Refrigerate (2-8°C)
- Precipitate may form but it can be resolubilized by allowing the drug to warm to room temperature and shaking vigorously
- Infusions are stable 24 hours at room temperature in NS
Compatibility:
- Solutions Compatible: saline solutions
- Additive/Above Cassette Compatible: no information
- Y-site Compatible: dexamethasone, diphenhydramine (Benadryl), ondansetron, potassium chloride, ranitidine, sodium bicarbonate
INCOMPATIBLE: dextrose solutions
Administration:
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
| SC | NO |
| IM | NO |
| IV Direct |
NO |
| IV Intermittent Infusion | YES Infusion time: usually over 2 hours |
| IV Continuous Infusion | YES Usual dilution: dilute daily dose in 500 mL NS, infuse over 24 hours |
Dosage:
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
- Pediatric: 6.2-9 mg/m2/day x 5 days
- Dosage in Myelosuppression:
- Usually none required; may require delay until count recovery
- Check protocol for specifics
** Dosage may differ according to protocol
Dosage adjustment in renal/hepatic impairement
- No information
Potential hazards of parenteral administration:
- Injection site redness, swelling, pain, thrombosis, phlebitis, cellulitis
- Rash
- Nausea (mild)
- Fever, headache, fatigue
- Non-vesicant
- Bone marrow suppression, nadir 7-14 days after therapy, recovery by 21-28 days
**Treatment for unusual side effects are available through the study chair identified on the front page of the protocol and/or pharmacy
Notes:
- Ensure adequate hydration during treatment
- If white count is high give allopurinol, hydration, and bicarbonate prior to first course
- Cumulative and prolonged thrombocytopenia can occur after multiple cycles
- Very high doses >0.26 mg/kg (8 mg/m2) x 10-14 days have been associated with CNS and renal toxicity in adults